Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPCA in Metastatic Esophageal and Gastric Cancer
NCT00394433Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2006
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in esophageal cancer, gastric cancer (GC), sponsored by Dana-Farber Cancer Institute. Started Sep 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT00394433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00394433.